AZN stock news · AstraZeneca
Get alerts for AZN
Follow AstraZeneca (AZN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AZNAstraZeneca's profit and sales grew last quarter, and it plans to save $1.5 billion to boost its drug lineup.
Good for AZNAstraZeneca reported third-quarter sales and profit growth, with Imfinzi sales up 26%. Positive trial news and planned research savings make the report favorable.
AstraZeneca and Daiichi Sankyo got the green light for their cancer drug Enhertu in China.
Good for AZNAstraZeneca and Daiichi Sankyo won conditional Chinese approval for another use of Enhertu. More patients may gain access, supporting AstraZeneca's cancer-drug business.
AstraZeneca says its new drug worked well in a year-long clinical trial.
Good for AZNAstraZeneca reported that a drug candidate helped more patients reach a state with no visible disease signs than a placebo. The result supports its drug-development work, though no approval or sales were reported.
AstraZeneca's Ultomiris got quick approval from the FDA to help patients with IgA nephropathy.
Good for AZNAstraZeneca won FDA accelerated approval for Ultomiris in certain adults with IgA kidney disease. The added use supports the company, though the story gives no estimate of added sales.
AstraZeneca has teamed up with Abu Dhabi groups to improve healthcare projects.
NeutralAstraZeneca formalized a partnership with Abu Dhabi groups and health organizations to support healthcare work. The story gives no specific results or financial terms, so it does not change the company's outlook.
AstraZeneca teams up with groups in Abu Dhabi to improve healthcare.
Good for AZNAstraZeneca signed a partnership with Abu Dhabi groups and health organizations. It may broaden its research network, so the news modestly supports the company.
AstraZeneca and Amgen's drug Tezspire helps many patients with eosinophilic esophagitis feel much better.
Good for AZNAstraZeneca and Amgen reported strong, lasting Tezspire study results for eosinophilic esophagitis. This supports a brighter outlook for AstraZeneca, though the report does not say the drug is approved for this disease.
A former banker says she's changing her investment approach because too much money is in just 7 companies.
NeutralAstraZeneca is named as an example of a successful business outside the United States. The story gives no new facts about its business, so its outlook is unchanged.
AstraZeneca reports that its rare disease medicine helps some patients with a bone disorder, even though it didn't meet a main goal.
Bad for AZNAstraZeneca's HICKORY trial missed its main walking-test goal, despite gains in fatigue and some patient groups. That weakens the case for this drug.
AstraZeneca is putting $2 billion into Summit Therapeutics after a lot of guessing about it.
NeutralAstraZeneca is investing $2 billion in Summit and will share the cost of drug-combination trials. The possible research gains remain unproven, so the story does not clearly change AstraZeneca's outlook.
AstraZeneca, Leidos, and Expeditors International were featured in CNBC's 'Final Trades' segment.
Good for AZNAstraZeneca won a breast cancer approval and posted strong Phase 3 results, which I read as favorable for AstraZeneca's growth prospects.
BioMarin aims to bolster its presence in the treatment of rare bone diseases.
NeutralComparison to AstraZeneca's Strensiq highlights the market potential for BioMarin's new asset in the HPP treatment space.
AstraZeneca delivers varied results from three key lung cancer studies.
NeutralAstraZeneca's announcement of mixed outcomes from its lung cancer trials presents both positive and negative implications for its drug pipeline. While the success in two trials may bolster its market position, the discontinuation of the eVOLVE-Lung02 study raises concerns about the viability of certain treatment combinations, impacting investor sentiment.